Skip to main content
Caplight Logo









Treme Bio

Treme Bio

Private
Atlanta, GeorgiaHealthcare & Life Scienceshttps://tremebio.com/

Last Round

Series B

Extension

Jan 27, 2026

Total Funding Raised

$219M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Treme Bio is a biotechnology company developing ProLymphNano, a patented drug delivery technology that focuses on the lymphatic system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platformlymphatic targetingnanoparticle drug deliverydrug delivery technologynanomedicinetargeted drug deliverybiotech licensingsustained releasedrug formulationpayload deliverybiodegradable nanoparticles

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Treme Bio Comparables

Compare Treme Bio with similar companies based on industry and business-model similarity.

Treme Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evoq Therapeutics
74%
Ropirio Therapeutics
69%
Elicio Therapeutics
69%

Treme Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 27, 2026
Series BNov 13, 2024
Series A ExtensionMar 8, 2022
Series AJun 22, 2021

Treme Bio Investors

Notable investors and investment history

Treme Bio investors
InvestorRounds
Janus Henderson GroupSeries B Extension
Agent CapitalSeries B
Balyasny Asset Management L.P.Series B Extension
SV Health InvestorsSeries B Extension, Series A, Series A Extension, Series B
Alexandria Venture InvestmentsSeries B Extension, Series A, Series A Extension, Series B
Delos Capital PartnersSeries B Extension, Series B
Polaris PartnersSeries B Extension, Series B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2026

    $50M raised from Alexandria Venture Investments and others.

  • Nov 13, 2024

    $84M round led by Delos Capital Partners.

Treme Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Treme Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Treme Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersAtlanta, Georgia
Year Founded2026
Last FundingJan 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?